Sjogren’s Syndrome – Epidemiology – Epidemiology Dashboard
DRG Epidemiology's coverage of rheumatoid arthritis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of rheumatoid arthritis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's rheumatoid arthritis forecast will answer the following questions:
- Of all people with rheumatoid arthritis, how many in each country across the world have been formally diagnosed?
- Of all people diagnosed with rheumatoid arthritis, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of rheumatoid arthritis over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following rheumatoid arthritis subpopulations:
- Total prevalent cases by diagnosis status
- Diagnosed prevalent cases by DAS28 severity status
- Diagnosed prevalent cases by drug-treatment status
Note: coverage may vary by country and region.
Table of contents
- Sjogren's Syndrome - Epidemiology - Epidemiology Dashboard
- Introduction
- Sjogren's syndrome Epidemiology Dashboard
- Introduction
Mohani Latwal, B.P.T., M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, she worked as a deputy manager at an NGO. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai.
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.